MDS

Myelodysplastic syndromes (MDS) are diseases of the blood cells and bone marrow. MDS are a collection of myeloid malignancies characterized by one or more peripheral blood cytopenias. Subtypes of this heterogeneous group of disorders occur when blood-forming cells in the bone marrow become abnormal. Sometimes, MDS precedes acute myeloid leukemia.

Advertisement
Advertisement
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | February 27, 2024
The CHMP of the European Medicines Agency recommended approval of luspatercept for transfusion-dependent anemia due to MDS.
Read More
Blood Cancer TalksAcute Myeloid Leukemia | February 13, 2024
Dr. Patel and the hosts discuss the TRANSFORM-1 study, MANIFEST-2, AUGMENT-101, and more.
Blood Cancers Today Staff WritersAcute Myeloid Leukemia | February 8, 2024
Gilead said that it "will not pursue further development of magrolimab in hematologic cancers."
Melissa BadamoAcute Myeloid Leukemia | February 8, 2024
Oral decitabine plus cedazuridine is a safe and effective alternative to intravenous decitabine.
Chadi Nabhan, MD, MBA, FACPMyelodysplastic Syndromes | February 14, 2024
This episode of The HemOnc Pulse features Dr. Shastri, a physician-scientist, who discusses latest news in MDS.
Sanjay Patel, MDVideo Insights | January 19, 2024
Sanjay Patel, MD, discusses a study on spatial mapping of human hematopoiesis using bone marrow tissue.
Melissa BadamoMyelodysplastic Syndromes | February 2, 2024
Complete response was achieved in 14 patients (22%) in the sabatolimab group, versus 11 patients (18%) in the placebo group.
Hana Safah, MDVideo Insights | January 24, 2024
The panel shares their outlook for the future of MDS research and treatment.
Hana Safah, MDVideo Insights | December 19, 2023
Dr. Tanaka outlines a biomarker study that observed reduced inflammation in patients with MDS treated with luspatercept.
Hana Safah, MDVideo Insights | December 19, 2023
The panel discussed a study that assessed quality of life and PROs in patients receiving luspatercept for MDS.
Hana Safah, MDVideo Insights | December 19, 2023
The panel discusses whether starting treatment with luspatercept sooner in patients with MDS is beneficial.
Hana Safah, MDVideo Insights | February 8, 2024
Dr. Shammo shares her reaction to a study that assessed mutational burden and impact on primary outcomes in COMMANDS.
Hana Safah, MDVideo Insights | December 19, 2023
Dr. Safah outlines the findings from the full analysis of the COMMANDS trial.
Hana Safah, MDVideo Insights | December 19, 2023
The panel discusses the evolution of MDS therapy.
Hana Safah, MDVideo Insights | January 12, 2024
Dr. Safah gave an overview of myelodysplastic syndromes.
Chadi Nabhan, MD, MBA, FACPThe HemOnc Pulse | January 17, 2024
Dr. Venugopal offers her thoughts on the investigational drug KER-050 in lower-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, MDVideo Insights | January 12, 2024
The panel discusses forward-looking thoughts for the treatment of low-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel talks about the use of transplant for patients with low-risk myelodysplastic syndromes.
Guillermo Garcia-Manero, MDVideo Insights | January 4, 2024
The panel discusses other treatments undergoing research for MDS, including imetelstat and KER-050.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel shared their thoughts on real-world data of luspatercept presented at ASH 2023.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel addresses continued MDS research needs.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel discusses appropriate treatment selection based on patient mutation status and comorbidities.
Guillermo Garcia-Manero, MDVideo Insights | December 18, 2023
The panel shares their thoughts on the full analysis of the COMMANDS study.
Guillermo Garcia-Manero, MDVideo Insights | January 4, 2024
The panel discussed the current slate of treatment options for patients with low-risk MDS.
Phillip Scheinberg, MDMyelodysplastic Syndromes | December 14, 2023
Dr. Schienberg discussed luspatercept in MDS, selinexor in AML, and the difficulty of randomizing trials.
Melissa BadamoMyelodysplastic Syndromes | December 13, 2023
The study compared somatic mutations and variant allele frequencies in paired peripheral blood and bone marrow samples.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | February 21, 2024
Dr. Guillermo Garcia-Manero outlined the final data update on luspatercept in patients with MDS in the COMMANDS trial.
Katie KoskoMeeting News | December 11, 2023
Investigators reviewed cladribine in combination with low dose cytarabine (LDAC) and venetoclax.
David Swoboda, MDMyelodysplastic Syndromes | January 3, 2024
In this video interview, Dr. Swoboda talks MDS highlights from ASH 2023, including the COMMANDS and IMerge trial.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | February 21, 2024
Targeted next-generation sequencing of the full UBA1 locus was used to profile diagnostic and treatment-naïve samples.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | December 13, 2023
Patients in the COMMANDS study were randomly assigned to luspatercept or epoetin alfa.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | December 13, 2023
Of the patients included in the study, 67.6% were not transfusion dependent before initiating luspatercept.
Leah LawrenceMyelodysplastic Syndromes | December 13, 2023
OS was still inversely proportional to the IPSS-M, but the molecular risk stratification had no additional prognostic power.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | December 13, 2023
Data differentiated the mechanisms of action of luspatercept from epoetin alfa in patients with transfusion-dependent LR-MDS.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | December 13, 2023
Baseline mutational burden impacted response to erythropoiesis-stimulating agents in naïve patients with lower-risk MDS.
Patrick DalyMyelodysplastic Syndromes | December 5, 2023
Venetoclax plus azacitidine was well tolerated and achieved favorable response rates in higher-risk myelodysplastic syndrome.
Blood Cancers Today Staff WritersMyelodysplastic Syndromes | December 13, 2023
Researchers studied patients with LR-MDS who had received an erythropoiesis-stimulating agent as frontline therapy.
Amer Zeidan, MBBS, MHSMyelodysplastic Syndromes | December 8, 2023
Amer Zeidan, MBBS, MHS, reflects on the COMMANDS study that compared luspatercept with epoetin alfa in MDS.
Rami Komrokji, MDMyelodysplastic Syndromes | February 21, 2024
Rami Komrokji, MD, discussed the impact of luspatercept on the genomic landscape in patients with lower-risk MDS.
Melissa BadamoMyelodysplastic Syndromes | November 27, 2023
The study determined the maximum tolerated dose of CPX-351, but further studies are needed to evaluate its activity.
Melissa BadamoMyelodysplastic Syndromes | November 27, 2023
The study evaluated mesenchymal cell molecular features and sought modifications that might affect MDS.
Guillermo Garcia-Manero, MDMyelodysplastic Syndromes | November 15, 2023
Guillermo Garcia-Manero, MD, discusses contemporary issues regarding the management of LR-MDS.
Leah SherwoodPrint | November 13, 2023
Clinicians weigh in on AI advances in hematological diagnoses, prognoses, and treatment.
Melissa BadamoMyelodysplastic Syndromes | November 3, 2023
Iron may participate in the pathophysiology of MDS by increasing genomic instability and altering the microenvironment.
Melissa BadamoAcute Myeloid Leukemia | November 6, 2023
RNA sequencing showed decreased gene expression levels of the NF-κB target genes IL1β and IER3 after emavusertib treatment.
Melissa BadamoMyelodysplastic Syndromes | November 1, 2023
Red blood cell transfusion independence (RBC-TI) ≥8 weeks during weeks 1-24 of treatment was associated with improved OS.
Melissa BadamoMyelodysplastic Syndromes | October 30, 2023
Factors “significantly associated with overall survival" include older age, male sex, monosomal karyotype, and more.
Melissa BadamoMyelodysplastic Syndromes | October 26, 2023
The October 24, 2023, approval was based on trial AG120-C-001 that evaluated the safety of ivosidenib.
Cecilia BrownMyelodysplastic Syndromes | October 25, 2023
The study enrolled 214 participants, including 111 patients with 39 different RUNX1 variants from 45 unrelated families.
Anne Sophie Kubasch, MDVideo Insights | October 25, 2023
Anne Sophie Kubasch, MD, of Leipzig University, speaks on the importance of MDS World Awareness Day.
Advertisement
Advertisement
Latest News

February 29, 2024